Sharpley Christopher F, Christie David R H, Bitsika Vicki
Brain-Behaviour Research Group, University of New England, Queen Elizabeth Drive, Armidale, NSW, 2351, Australia,
Int J Clin Oncol. 2014;19(3):523-30. doi: 10.1007/s10147-013-0569-y. Epub 2013 Jun 1.
To investigate the relationship between hormone therapy (HT) and incidence of anxiety and depression among prostate cancer patients (PCa).
526 PCa patients completed a survey about their cancer status, treatment received, anxiety, and depression status. Total scores on anxiety and depression inventories, plus symptom profiles that discriminated between patients with current HT, past HT, and never having received HT, were compiled for analysis.
Patients who were currently receiving HT had significantly higher total anxiety and depression scores than patients who had previously received HT or who had never received HT. Analysis of the symptoms of anxiety and depression which distinguished between these groups of patients suggested that patients who had never received HT had significantly lower scores than current or past HT patients. Although several symptoms could be directly allocated to PCa and/or HT, symptom profiles were indicative of clinically significant anxiety and/or depression in patients who were currently receiving, or who had previously received, HT.
Current HT may lead to symptoms of anxiety and/or depression which require clinical attention. These effects seem to decrease after completion of HT.
探讨激素治疗（HT）与前列腺癌患者（PCa）焦虑和抑郁发生率之间的关系。
526例PCa患者完成了一项关于其癌症状况、接受的治疗、焦虑和抑郁状况的调查。汇总焦虑和抑郁量表的总分，以及区分当前接受HT、过去接受HT和从未接受过HT的患者的症状概况，进行分析。
当前正在接受HT的患者的焦虑和抑郁总分显著高于既往接受过HT或从未接受过HT的患者。对区分这些患者组的焦虑和抑郁症状的分析表明，从未接受过HT的患者的得分显著低于当前或过去接受过HT的患者。尽管几种症状可直接归因于PCa和/或HT，但症状概况表明，当前正在接受或既往接受过HT的患者存在具有临床意义的焦虑和/或抑郁。
当前的HT可能导致焦虑和/或抑郁症状，需要临床关注。这些影响在HT结束后似乎会减弱。
